CEOIllexcor TherapeuticsPhiladelphia, Pennsylvania, United States
Disclosure information not submitted.
ILX-002 – A Direct HbS Polymerization Inhibitor for the Treatment of Sickle Cell Disease
Saturday, June 8, 20246:00 PM – 7:00 PM ET